Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2013

Open Access 01-12-2013 | Case report

Combined large cell neuroendocrine carcinoma with giant cell carcinoma of the lungs: a case report

Authors: Satoshi Hayashi, Masahiro Kitada, Kei Ishibashi, Yoshinari Matsuda, Naoyuki Miyokawa

Published in: World Journal of Surgical Oncology | Issue 1/2013

Login to get access

Abstract

Combined large cell neuroendocrine carcinoma of the lungs (combined LCNEC) with giant cell carcinoma is extremely rare. A 65-year-old man was found to have an abnormal shadow in his left lung field. Computed tomography revealed a solid, round mass measuring 2.8 × 2.2 cm that was located in the left S9. The patient underwent left lower lobectomy and mediastinal lymph node dissection. Histopathological examination revealed an LCNEC, combined with giant cell carcinoma. The patient received by S-1 (TS-1, an oral fluoropyrimidine) chemotherapy, and he has been disease-free for over 8 months. Combined LCNEC with giant cell carcinoma is an extremely rare tumor with high malignant potential, and thus, multidisciplinary therapy and close follow-up are advised.
Appendix
Available only for authorised users
Literature
1.
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC: World Health Organization Classification of Tumours. Tumours of the Lung, Pleura, Thymus and Heart: Pathology and Genetics. 2004, Lyon: International Agency for Research on Cancer Press
2.
Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K, Nagai K: Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006, 24: 70-76. 10.1200/JCO.2005.04.1202.CrossRefPubMed
3.
Oshiro Y, Kusumoto M, Matsuno Y, Asamura H, Tsuchiya R, Terasaki H, Takei H, Maeshima A, Murayama S, Moriyama N: CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. Am J Roentgenol. 2004, 182: 87-91. 10.2214/ajr.182.1.1820087.CrossRef
4.
Sturm N, Lantuéjoul S, Laverrière MH, Papotti M, Brichon PY, Brambilla C, Brambilla E: Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol. 2001, 32: 918-925. 10.1053/hupa.2001.27110.CrossRefPubMed
5.
Sarkaria IS, Iyoda A, Roh MS, Sica G, Kuk D, Sima CS, Pietanza MC, Park BJ, Travis WD, Rusch VW: Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Ann Thorac Surg. 2011, 92: 1180-1187. 10.1016/j.athoracsur.2011.05.027.CrossRefPubMed
6.
Battafarano RJ, Fernandez FG, Ritter J, Meyers BF, Guthrie TJ, Cooper JD, Patterson GA: Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005, 130: 166-172. 10.1016/j.jtcvs.2005.02.064.CrossRefPubMed
7.
Howe MC, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS: Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology. 2005, 46: 195-201. 10.1111/j.1365-2559.2005.02047.x.CrossRefPubMed
8.
Petrović M, Baskić D, Banković D, Ilić N: Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer. Biomarkers. 2011, 16: 311-320. 10.3109/1354750X.2011.560281.CrossRefPubMed
9.
Harada M, Yokose T, Yoshida J, Nishiwaki Y, Nagai K: Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung. Lung Cancer. 2002, 38: 177-184. 10.1016/S0169-5002(02)00181-2.CrossRefPubMed
Metadata
Title
Combined large cell neuroendocrine carcinoma with giant cell carcinoma of the lungs: a case report
Authors
Satoshi Hayashi
Masahiro Kitada
Kei Ishibashi
Yoshinari Matsuda
Naoyuki Miyokawa
Publication date
01-12-2013
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2013
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-11-205

Other articles of this Issue 1/2013

World Journal of Surgical Oncology 1/2013 Go to the issue

Research

Fast access and early ligation of the renal pedicle significantly facilitates retroperitoneal laparoscopic radical nephrectomy procedures: modified laparoscopic radical nephrectomy

Research

Factors associated with receipt of adjuvant chemotherapy among married women with breast cancer

Research

The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas

Case report

Multiple bilateral oncocytomas of the native kidneys following renal transplantation: report of a rare case and review of the literature

Research

Preventive effect of ulinastatin on postoperative complications, immunosuppression, and recurrence in esophagectomy patients

Case report

The imaging and pathological features of a mucinous tubular and spindle cell carcinoma of the kidney: a case report